240 related articles for article (PubMed ID: 33143357)
1. Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib.
Lee Y; Kim J; Kim W; Yoon IS; Jung Y
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33143357
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.
Lee S; Lee Y; Kim W; Nam J; Jeong S; Yoo JW; Kim MS; Moon HR; Jung Y
Drug Des Devel Ther; 2015; 9():4227-37. PubMed ID: 26300626
[TBL] [Abstract][Full Text] [Related]
3. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
Lee Y; Kim J; Kim H; Kang S; Yoon JH; Kim DD; Kim YM; Jung Y
J Pharm Sci; 2012 May; 101(5):1831-42. PubMed ID: 22334096
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
Li MH; Yin LL; Cai MJ; Zhang WY; Huang Y; Wang X; Zhu XZ; Shen JK
Acta Pharmacol Sin; 2005 Jul; 26(7):865-72. PubMed ID: 15960895
[TBL] [Abstract][Full Text] [Related]
5. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Lee Y; Kim J; Kim W; Nam J; Jeong S; Lee S; Yoo JW; Kim MS; Jung Y
Drug Des Devel Ther; 2015; 9():4105-13. PubMed ID: 26251576
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.
Mamidi RN; Mullangi R; Kota J; Bhamidipati R; Khan AA; Katneni K; Datla S; Singh SK; Rao KY; Rao CS; Srinivas NR; Rajagopalan R
Biopharm Drug Dispos; 2002 Oct; 23(7):273-82. PubMed ID: 12355578
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
9. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
Madhava G; Ramana KV; Sudhana SM; Rao DS; Kumar KH; Lokanatha V; Rani AU; Raju CN
Med Chem; 2017; 13(5):484-497. PubMed ID: 28228088
[TBL] [Abstract][Full Text] [Related]
10. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
Malmborg J; Ploeger BA
J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
[TBL] [Abstract][Full Text] [Related]
11. Biological Screening of Novel Structural Analog of Celecoxib as Potential Anti-Inflammatory and Analgesic Agent.
Zlatanova H; Vladimirova S; Kostadinov I; Delev D; Deneva T; Kostadinova I
Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30959829
[No Abstract] [Full Text] [Related]
12. Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Kaur K; Jain S; Sapra B; Tiwary AK
Curr Drug Deliv; 2007 Oct; 4(4):276-82. PubMed ID: 17979648
[TBL] [Abstract][Full Text] [Related]
13. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
14. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Pinheiro RM; Calixto JB
Inflamm Res; 2002 Dec; 51(12):603-10. PubMed ID: 12558194
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of transdermal patches of celecoxib.
Alam MI; Baboota S; Kohli K; Ali J; Ahuja A
PDA J Pharm Sci Technol; 2009; 63(5):429-37. PubMed ID: 20158049
[TBL] [Abstract][Full Text] [Related]
17. Formulation development of self-nanoemulsifying drug delivery system of celecoxib for the management of oral cavity inflammation.
Salem HF; Kharshoum RM; Sayed OM; Abdel Hakim LF
J Liposome Res; 2019 Jun; 29(2):195-205. PubMed ID: 30221598
[TBL] [Abstract][Full Text] [Related]
18. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration.
Minami K; Hirayama F; Uekama K
J Pharm Sci; 1998 Jun; 87(6):715-20. PubMed ID: 9607948
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model.
Kalangi SK; Swarnakar NK; Sathyavathi R; Narayana Rao D; Jain S; Reddanna P
Oxid Med Cell Longev; 2018; 2018():3090517. PubMed ID: 30046374
[TBL] [Abstract][Full Text] [Related]
20. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
Jain SK; Gupta Y; Jain A; Bhola M
Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
